Cargando…

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma have a better overall survival than those with residual disease. Many classification systems assessing pathological response to neoadjuvant chemotherapy include residual ductal carcinoma in situ (DC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, R L, Lakhani, S R, Ring, A E, Ashley, S, Walsh, G, Smith, I E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361141/ https://www.ncbi.nlm.nih.gov/pubmed/16421590 http://dx.doi.org/10.1038/sj.bjc.6602950

Ejemplares similares

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
por: Ring, A E, et al.
Publicado: (2004)

The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS
por: Wallis, M G, et al.
Publicado: (2012)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary?
por: Boler, D. E., et al.
Publicado: (2012)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
por: Marinovich, M L, et al.
Publicado: (2013)

Higher Volume at Time of Breast Conserving Surgery Reduces Re-Excision in DCIS
por: Wolf, J. H., et al.
Publicado: (2011)

Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer
por: Chen, Yong-He, et al.
Publicado: (2020)

Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer
por: Bhattacharyya, M, et al.
Publicado: (2008)

Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022)

Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate?
por: Powles, T, et al.
Publicado: (2006)

Clinical Outcome of Patients with Complete Pathological Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancers: The Indian Scenario
por: Sinukumar, Snita, et al.
Publicado: (2014)

Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
por: Glynne-Jones, R, et al.
Publicado: (2006)

Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
por: Kaewkangsadan, Viriya, et al.
Publicado: (2016)

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
por: McCormack, M, et al.
Publicado: (2013)

Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study
por: Holmberg, L, et al.
Publicado: (2013)

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
por: Guiu, S, et al.
Publicado: (2010)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates
por: Lin, J-C, et al.
Publicado: (2003)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

Is palpable DCIS more aggressive than screen-detected DCIS?
por: Balac, Nina, et al.
Publicado: (2022)

Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy
por: Gómez, Rodolfo, et al.
Publicado: (2015)

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
por: Delpech, Y, et al.
Publicado: (2013)

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy
por: Herrero-Vicent, C, et al.
Publicado: (2016)

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
por: Hinsenveld, F. J., et al.
Publicado: (2021)

Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma
por: Fields, R C, et al.
Publicado: (2011)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer?
por: Evans, A, et al.
Publicado: (2013)

Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data
por: Saffie Vega, Isabel, et al.
Publicado: (2022)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study
por: Balmativola, D., et al.
Publicado: (2014)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
por: Dose-Schwarz, J, et al.
Publicado: (2010)

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review
por: Lobbes, M. B. I., et al.
Publicado: (2013)

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
por: Pinder, S E, et al.
Publicado: (2010)

Inulin Supplementation Reduces Systolic Blood Pressure in Women with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Becerril-Alarcón, Yizel, et al.
Publicado: (2019)

The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy
por: Roininen, Nelli, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in technically unresectable head and neck cancers: a retrospective audit
por: Mishra, Bal Krishna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gsndrnpoi23eevqtopl4o0ebpu